Rupert Dixon, Ph.D., is a Senior Director, Principal Scientific Advisor in the Strategic Drug Development group of QuintilesIMS Consulting Services. In this role, Rupert provides leadership of cross-functional and cross-organizational teams to design, plan and deliver drug development strategies, projects and programs
Rupert has 20 years’ experience in the pharmaceutical industry. Prior to joining QuintilesIMS in 2016, he held clinical development roles at Wyeth, Eisai, Mitsubishi and most recently at AstraZeneca, where he led clinical projects for a number of late-stage assets. Integral with these roles, Rupert has developed deep insights and experience in team effectiveness and partnering models in the drug development arena.
Rupert received a BSc in Zoology and Ph.D. in Neurosciences from Newcastle University, UK and held a post-doctoral fellowship at the University of Padova, Italy before moving into the pharmaceutical industry in 1997.